Table 1.
Baseline Characteristics of Statin‐Users and Nonusers
| Total (n=5718) | Statin Users (n=4166) N (%) | Nonusers (n=1552) N (%) | P Value | |
|---|---|---|---|---|
| Demographics | ||||
|
Age (median) (y) Mean age (SD) |
74 75 (6.1) |
74 75 (5.8) |
75 76 (6.8) |
<0.0001 |
| Age categories (y) | ||||
| 66–70 | 1610 (28) | 1223 (29) | 387 (25) | <0.0001 |
| 71–75 | 1619 (28) | 1201 (29) | 418 (27) | |
| 76–80 | 1375 (24) | 1027 (25) | 348 (22) | |
| 81 and over | 1114 (19) | 715 (17) | 399 (26) | |
| Sex (female) | 2595 (45) | 1807 (43) | 788 (51) | <0.0001 |
| Cardiovascular risk factors | ||||
| Hypertension | 4062 (71) | 3075 (74) | 987 (64) | <0.0001 |
| Diabetes mellitus | 1702 (30) | 1322 (32) | 380 (24) | <0.0001 |
| Dyslipidemia | 3572 (62) | 3079 (74) | 493 (32) | <0.0001 |
| Carotid artery disease | 286 (5) | 237 (6) | 49 (3) | <0.0001 |
| CAD | 4942 (86) | 3696 (89) | 1246 (80) | <0.0001 |
| PVD | 388 (7) | 316 (8) | 72 (5) | <0.0001 |
| Heart failure | 1261 (22) | 925 (22) | 336 (22) | 0.65 |
| CKD | 836 (15) | 632 (15) | 204 (13) | 0.0538 |
| Atrial fibrillation | 1195 (21) | 846 (20) | 349 (22) | 0.07 |
| Prior stroke | 597 (10) | 466 (11) | 131 (8) | 0.002 |
| Prior MI | 1773 (31) | 1397 (34) | 376 (24) | <0.0001 |
| Prior MI/CAD | 5199 (91) | 3855 (93) | 1344 (87) | <0.0001 |
| Cancer type | 0.10 | |||
| Head and neck | 689 (12) | 520 (12) | 169 (11) | |
| Chest and mediastinal | 5029 (88) | 3646 (88) | 1383 (89) | |
| Cancer therapy | ||||
| Chemotherapy | 1138 (20) | 840 (20) | 298 (19) | 0.42 |
| medication | ||||
| Aspirin | 3280 (57) | 2754 (66) | 526 (34) | <0.0001 |
| ACEI | 2735 (48) | 2300 (55) | 435 (28) | <0.0001 |
| ARB | 1130 (20) | 948 (23) | 182 (12) | <0.0001 |
| BB | 1563 (27) | 1298 (31) | 265 (17) | <0.0001 |
| CCB | 1565 (27) | 1316 (32) | 249 (16) | <0.0001 |
| Clopidogrel | 827 (14) | 751 (18) | 76 (5) | <0.0001 |
| Warfarin | 859 (15) | 654 (16) | 205 (13) | 0.02 |
ACEI indicates angiotensin‐converting enzyme inhibitor; ARB, angiotensin‐receptor blocker; BB, β‐blocker; CAD, coronary artery disease; CCB, calcium channel blocker; CKD, chronic kidney disease; MI, myocardial infarction; PVD, peripheral vascular disease.